Abstract: A method for differentiating a human differentiated cell-derived pluripotent stem cell into a neural stem cell is provided, which includes the steps of: making an embryoid body from the human differentiated cell-derived pluripotent stem cell; and culturing the embryoid body in a medium containing LIF to differentiate into a neural stem cell, so that, when the neural stem cell is allowed to differentiate in vitro after multiple subculturing of the neural stem cell, it differentiate mainly into neurons but substantially not into glial cells.
Abstract: The invention relates to methods for obtaining antibodies that recognize amyloid protofibrils and antibodies that recognize one or more amyloid protofibrils. Also provided are methods of using the antibodies to prevent or inhibit amyloid disease in a subject, to diagnose amyloid disease in a subject, and to detect amyloid protofibrils in a sample.
Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
July 24, 2018
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
July 17, 2018
Assignee:
GENZYME CORPORATION
Inventors:
Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
Abstract: The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterized by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterized by neuronal injury or death, or axonal degeneration.
Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
June 19, 2018
Assignee:
Eli Lilly and Company
Inventors:
Patrick Cornelious May, Dustin James Mergott
Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.
Abstract: A method for producing an engineered tissue scaffold for neural repair is described. The method includes tethering a hydrogel matrix seeded with tension-generating cells to a frame, and allowing the tension-generating cells to generate tension within the matrix, such that the cells self-align. The matrix may then be at least partially dehydrated to form a sheet. The tension-generating cells are stem cells capable of differentiating into cells having Schwann-cell-like properties, or are derived from such stem cells. In preferred embodiments, the cells are neural stem cells, for example conditionally immortalized neural stem cells of fetal cortex origin.
Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
Type:
Grant
Filed:
July 20, 2011
Date of Patent:
May 29, 2018
Assignee:
Washington University
Inventors:
Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.
Type:
Grant
Filed:
August 16, 2017
Date of Patent:
May 29, 2018
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: —contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSyn-comprising-aggregates, and —detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).
Type:
Grant
Filed:
April 2, 2014
Date of Patent:
May 8, 2018
Assignee:
AFFIRIS AG
Inventors:
Guenther Staffler, Markus Mandler, Andreas Mairhofer, Arne Von Bonin
Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
May 1, 2018
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
Type:
Grant
Filed:
May 16, 2016
Date of Patent:
April 24, 2018
Assignees:
ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
Inventors:
Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
Abstract: The present invention provides a method for isolating human neural stem cells from amniotic fluid of a patient whose fetus has been diagnosed to have a neural tube defect. Use of the isolated human neural stem cells in the treatment of neurological disorders is also provided.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
April 17, 2018
Assignee:
FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE
Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
Type:
Grant
Filed:
January 10, 2017
Date of Patent:
April 17, 2018
Assignee:
Eli Lilly and Company
Inventors:
Ronald Bradley DeMattos, Jirong Lu, Ying Tang
Abstract: Non-invasive method for diagnosing or prognosing Alzheimer's disease, frontotemporal dementia, or other dementia involving isolating astrocyte-derived exosomes (ADEs) and neuron-derived exosomes (NDEs) from a human biological sample (i.e., plasma, serum, urine or cerebrospinal fluid), analyzing cargo extracts of the ADEs and NDEs to detect at least one specified protein or microRNA biomarker, comparing the levels and activities of detected biomarker(s) to those in control samples to identify a statistically significant difference between the detected biomarker(s) and corresponding biomarker(s) in the control sample to determine presence of Alzheimer's disease, frontotemporal dementia, or other dementia; and testing effects of drugs on levels and activities of each biomarker, as well as effects of drugs administered to test subjects on levels and activities of each biomarker in ADEs and NDEs from subsequently obtained biological samples.
Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
Type:
Grant
Filed:
September 11, 2015
Date of Patent:
March 6, 2018
Assignees:
AMPRION, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
Abstract: The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (A?), including Alzheimer's disease. Enabled herein is a reagent for use in the treatment and prophylaxis of A?-associated pathological conditions.
Type:
Grant
Filed:
August 5, 2014
Date of Patent:
March 6, 2018
Assignee:
St. Vincent's Institute of Medical Research
Inventors:
Luke Anthony Miles, Michael William Parker, Tracy Leah Nero